Nizar Tannir

29PUBLICATIONS
270CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Cancer diagnosisCancer geneticsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (29)

|Aug 21, 2026
Panitumumab-Based EGFR Blockade in SMARCB1-Deficient Renal Medullary Carcinoma: Preclinical Basis and Prospective Clinical Activity.

|Jul 14, 2026
Allogeneic CD70-Targeted Chimeric Antigen Receptor T-Cell Therapy for Advanced Renal Cell Carcinoma: Results From the Phase I TRAVERSE Trial.

|May 16, 2026
Addition of Metastasis-Directed Therapy to Standard of Care for Oligometastatic Disease: Primary Aggregated Analysis of All Baskets from the Phase II Randomized EXTEND Trial.

|Apr 20, 2026
Phase II Trial of Ixazomib Combined with Gemcitabine and Doxorubicin in Patients with SMARCB1-Deficient Renal Medullary Carcinoma.

|Mar 30, 2026
Efficacy of Immune Checkpoint Blockade in Advanced Upper Tract Urothelial Cancer With DNA Mismatch Repair Deficiency or Microsatellite Instability.

Mohammad Jad Moussa, Alexander Y Andreev-Drakhlin, Aradhana M Venkatesan

|Mar 26, 2026
Tazemetostat, an EZH2 inhibitor, in solid tumors harboring SWI/SNF alterations: a phase II basket study.

Mrinal Gounder, Patrick Schöffski, Robin L Jones

Pageof 5

Frequent Collaborators

15 joint publications

Pavlos Msaouel

7 joint publications

Priya Rao

6 joint publications

Omar Alhalabi

6 joint publications

Jianjun Gao